SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

AnnJi files U.S. FDA application for Phase 3 AJ201 trial

AnnJi Pharmaceutical Co Ltd has submitted an application to the U.S. FDA for a Phase 3 clinical trial of AJ201.

7754

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.